Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDS Pathway for Respiratory Complications
NCT04263363Phase 4Completed
- Sponsor
- University of California, Los Angeles
- Start
- Feb 2022
- Primary completion
- May 2024
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by University of California, Los Angeles. Primary endpoints: Time to "Fitness for Discharge" From the Recovery Room at 1 year and Incidence of Hypoxemia in the PACU (Oxygen Saturation Below 90%) at 1 year. Started Feb 2022; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT04263363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263363.